112 related articles for article (PubMed ID: 23806811)
1. Profiling biopharmaceutical deciding properties of absorption of lansoprazole enteric-coated tablets using gastrointestinal simulation technology.
Wu C; Sun L; Sun J; Yang Y; Ren C; Ai X; Lian H; He Z
Int J Pharm; 2013 Sep; 453(2):300-6. PubMed ID: 23806811
[TBL] [Abstract][Full Text] [Related]
2. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
3. Eudragit L/HPMCAS blend enteric-coated lansoprazole pellets: enhanced drug stability and oral bioavailability.
Fang Y; Wang G; Zhang R; Liu Z; Liu Z; Wu X; Cao D
AAPS PharmSciTech; 2014 Jun; 15(3):513-21. PubMed ID: 24590548
[TBL] [Abstract][Full Text] [Related]
4. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
Kuentz M; Nick S; Parrott N; Röthlisberger D
Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
[TBL] [Abstract][Full Text] [Related]
5. A case study on the in silico absorption simulations of levothyroxine sodium immediate-release tablets.
Kocic I; Homsek I; Dacevic M; Grbic S; Parojcic J; Vucicevic K; Prostran M; Miljkovic B
Biopharm Drug Dispos; 2012 Apr; 33(3):146-59. PubMed ID: 22374714
[TBL] [Abstract][Full Text] [Related]
6. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
Liu F; Shokrollahi H
Int J Pharm; 2015 May; 485(1-2):152-9. PubMed ID: 25746736
[TBL] [Abstract][Full Text] [Related]
7. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation.
Kovacević I; Parojcić J; Homsek I; Tubić-Grozdanis M; Langguth P
Mol Pharm; 2009; 6(1):40-7. PubMed ID: 19248231
[TBL] [Abstract][Full Text] [Related]
8. In vitro-in vivo-in silico approach in biopharmaceutical characterization of ibuprofen IR and SR tablets.
Beloica S; Cvijić S; Bogataj M; Parojčić J
Eur J Pharm Sci; 2015 Jul; 75():151-9. PubMed ID: 25861718
[TBL] [Abstract][Full Text] [Related]
9. High-performance thin-layer chromatographic method for the detection and determination of lansoprazole in human plasma and its use in pharmacokinetic studies.
Pandya KK; Mody VD; Satia MC; Modi IA; Modi RI; Chakravarthy BK; Gandhi TP
J Chromatogr B Biomed Sci Appl; 1997 May; 693(1):199-204. PubMed ID: 9200535
[TBL] [Abstract][Full Text] [Related]
10. In vitro--in silico--in vivo drug absorption model development based on mechanistic gastrointestinal simulation and artificial neural networks: nifedipine osmotic release tablets case study.
Ilić M; Ðuriš J; Kovačević I; Ibrić S; Parojčić J
Eur J Pharm Sci; 2014 Oct; 62():212-8. PubMed ID: 24911992
[TBL] [Abstract][Full Text] [Related]
11. Development of Dexlansoprazole Delayed-Release Capsules, a Dual Delayed-Release Proton Pump Inhibitor.
Grady H; Murakawa Y; Mulford D; Kukulka M
J Pharm Sci; 2019 Nov; 108(11):3496-3501. PubMed ID: 31386865
[TBL] [Abstract][Full Text] [Related]
12. The effect of food and antacids on lansoprazole absorption and disposition.
Delhotal-Landes B; Cournot A; Vermerie N; Dellatolas F; Benoit M; Flouvat B
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():315-20. PubMed ID: 1820900
[TBL] [Abstract][Full Text] [Related]
13. Novel lansoprazole-loaded nanoparticles for the treatment of gastric acid secretion-related ulcers: in vitro and in vivo pharmacokinetic pharmacodynamic evaluation.
Alai M; Lin WJ
AAPS J; 2014 May; 16(3):361-72. PubMed ID: 24519468
[TBL] [Abstract][Full Text] [Related]
14. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: extension to describe performance of solid dosage forms.
Thelen K; Coboeken K; Willmann S; Dressman JB; Lippert J
J Pharm Sci; 2012 Mar; 101(3):1267-80. PubMed ID: 22125236
[TBL] [Abstract][Full Text] [Related]
15. Formulation study for lansoprazole fast-disintegrating tablet. II. Effect of triethyl citrate on the quality of the products.
Shimizu T; Kameoka N; Iki H; Tabata T; Hamaguchi N; Igari Y
Chem Pharm Bull (Tokyo); 2003 Sep; 51(9):1029-35. PubMed ID: 12951443
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium.
Wang-Smith L; Fort J; Zhang Y; Sostek M
J Clin Pharmacol; 2012 May; 52(5):670-80. PubMed ID: 21628602
[TBL] [Abstract][Full Text] [Related]
17. Uneven Distribution of Microgranules in Divided Lansoprazole Tablets.
Teitelbaum GA; Teitelbaum JE
J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):437-9. PubMed ID: 25885882
[TBL] [Abstract][Full Text] [Related]
18. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.
Shono Y; Jantratid E; Dressman JB
Eur J Pharm Biopharm; 2011 Oct; 79(2):349-56. PubMed ID: 21527341
[TBL] [Abstract][Full Text] [Related]
19. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
Kortejärvi H; Urtti A; Yliperttula M
Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
